XYL Xylem Inc. Insider Trading

Director Peribere makes first open-market purchase of 1,210 shares after prior stock-comp-only activity; stock trades well below 52-week highs as company maintains profitability.

Peribere Jerome A, a director at Xylem, deployed personal capital to purchase shares on the open market for the first time in at least three years—a shift from his prior activity, which consisted solely of stock-based compensation transactions. The timing aligns with the stock trading meaningfully below its 52-week high and down over recent quarters, effectively allowing him to add to his stake at reduced prices. Xylem remains a profitable, revenue-growing company, so this purchase is into a fundamentally sound business rather than a turnaround situation. As a first open-market buy, this transaction breaks his historical pattern and suggests a decision to increase direct exposure beyond what his compensation package alone would provide.

EVP Claudia Toussaint sold 10,421 shares of XYL at $152.64; holdings reduced 25.0% to 31,250 shares.

Claudia Toussaint, EVP and CPSO, sold 10,421 shares at $152.64 on 2025-10-30, reducing her position by 25.0% to 31,250 shares post-transaction. The sale occurred near the 52-week high of $152.95, with current price at $150.85. Against her cross-ticker track record of 1 prior sell with a 90-day well-timed rate of 0.00%, her only prior trade at XYL (a February 2024 sell) was also not well-timed, with the stock returning +15.5% in the 90 days following. The company shows strong fundamentals: $2.3B revenue, +16.3% annual growth, and $227.0M net income, though trading at a P/E of 38.78. The timing relative to price levels offers limited directional clarity given the insider's historical miss-timing pattern at this specific ticker.

VP/Controller McShane sells 4,119 XYL shares at $128.18; holdings cut 51.0% to 3,950 shares

McShane Geri-Michelle, serving as VP, Controller & CAO, sold 4,119 shares of Xylem at $128.18 on 2025-03-07, reducing her holdings by 51.0% from 8,069 shares to 3,950 shares. The sale totaled $527,977.95 and occurred at a price 1.87% below the current market price of $130.62, within the 52-week range of $114.02–$145.95. As a finance executive (controller role), this transaction warrants examination of context: the company's 16.3% annual revenue growth, $2.1B quarterly revenue, and P/E of 28.58 suggest operational health, though the magnitude of her equity reduction—cutting her stake in half—represents a material change in her ownership position. The timing relative to company performance and any scheduled trading arrangements requires review to determine whether the sale reflects a deliberate reduction in concentration or follows a pre-arranged plan.

SVP & General Counsel Trefon sells 12,026 shares of XYL at $127.26; post-sale holdings fall to 9,413 shares (-56.1%)

Dorothy Trefon, SVP & General Counsel at Xylem Inc., sold 12,026 shares for $1,530,391.48 on 2025-03-04, reducing her direct holdings by more than half from 21,439 to 9,413 shares. The sale occurred at $127.26, which was 11.6% below the 52-week high and 1.4% below the current price of $128.96, suggesting the transaction was neither executed during an extended peak nor at a marked discount. Xylem reported strong recent fundamentals with 16.3% annual revenue growth, $2.1B quarterly revenue, and a P/E of 28.22. The material reduction in the General Counsel's equity stake warrants monitoring, though the absence of broader insider activity data limits assessment of whether this reflects a systematic or isolated decision by management.

Director Tretikov executes offsetting buy/sell pair: 4 shares at $131.98, then 4 at $119.96

Tretikov Lila, a Director at Xylem Inc., executed two separate offsetting transactions within a 10-day window: purchasing 4 shares at $131.98 on 2024-10-22, then selling the same 4 shares at $119.96 on 2024-11-01. The sale occurred at a price $11.02 lower than the purchase, resulting in a realized loss of $48.08 on a 4-share position. The pattern shows equal quantities in opposing directions with no net position change (7,380 shares held post-transaction), suggesting the trades may reflect a matched pair rather than a directional conviction signal. With XYL currently trading at $127.01 (down 13.0% from its 52-week high of $145.95), the insider's near-term price action provides minimal signal to investors about medium-term outlook.